High-dose supplements of docosahexaenoic acid (DHA), an omega-3 fatty acid, penetrated the brain in both APOE4 carriers and non-carriers before dementia onset, the placebo-controlled PreventE4 trial ...

Humans carry a gene called APOE, which encodes for a protein called apolipoprotein E. There are variations in the sequence of this gene that create genetic variants of APOE, and one of those variants: ...

Early, Sustained and Statistically Significant Reduction in Plasma P-tau 181 Reaching 31% at 24 Months Observed in Carriers of One or Two Copies of APOE4 Gene, who Represent Two Thirds of Alzheimer’s ...

Anti-amyloid drugs likely have little effect on non-APOE4 carriers. Anti-amyloid antibody drugs may have an effect on APOE4 carriers, but with serious and potentially fatal side effects. Safety issues ...

CHICAGO (Reuters) -People who carry two copies of the APOE4 gene are virtually guaranteed to develop Alzheimer's and face symptoms at an earlier age, researchers reported on Monday in a study that ...

A new genetic variant in individuals who are APOE4 carriers is linked to a 70% reduction in the risk for Alzheimer's disease (AD), new research suggested. The variant occurs on the fibronectin 1 (FN1) ...

Apolipoprotein E epsilon 4 (APOE4) is the primary genetic risk factor for late-onset Alzheimer's disease (AD). APOE4 carriers, especially females, tend to develop gut dysbiosis earlier than ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s ...

HONG KONG, Jan 8 (Reuters) - A gene that predisposes its carriers to Alzheimer's disease appears to kick in only in old age and has nothing to do with mental declines that are sometimes seen early in ...

Phoenix platform matches users with genetically similar people to predict which interventions actually work. SINGAPORE, July 18, 2025 (GLOBE NEWSWIRE) -- The Phoenix today launched the alpha version ...

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for ...